2030년까지 중동 및 아프리카 유방암 치료제 시장 전망 - 지역 분석 - 약물 치료[표적 약물 치료(Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab 및 기타 표적 약물 치료), 호르몬 약물 치료(선택적 에스트로겐 수용체 조절제, 아로마타제 억제제 및 선택적 에스트로겐 수용체 하향조절제), 화학요법 및 면역요법/생물학적 요법], 유방암 유형(호르몬 수용체, HER2+ 및 삼중 음성 유방암) 및 유통 채널(병원 약국, 약국 및 소매 약국, 온라인 약국)
유방암 부담 증가로 중동 및 아프리카 유방암 치료제 시장 성장
유방암은 가장 흔한 질병으로 간주됩니다 전 세계 여성들 사이에서 암이 발생하고 있으며, 그 발병률은 전 세계적으로 증가하고 있습니다. 생활방식의 변화, 호르몬 불균형, 유전적 소인, 환경적 요인 등의 요인이 유방암 발병률을 높이는 원인이 됩니다. WHO에 따르면 2020년 전 세계적으로 685,000명이 유방암으로 사망했으며, 이는 230만 건의 새로운 유방암 진단에 해당합니다. 유방암은 전 세계적으로 가장 흔한 암 중 하나이며, 2020년 말 기준으로 지난 5년 이내에 유방암 진단을 받은 여성이 780만 명에 달합니다. 전 세계적으로 유방암은 청소년기 이후 모든 연령대의 여성에게 영향을 미칩니다. 그러나 나이가 들수록 유병률이 증가합니다. 유방암 사례가 증가함에 따라 환자 결과를 개선하기 위한 효과적이고 표적화된 치료법에 대한 필요성이 증가하고 있습니다. 이로 인해 유방암 치료제에 대한 연구 개발 활동이 급증하게 되었습니다. 따라서 유방암 부담 증가는 중동 및 아프리카 유방암 치료제 시장을 주도하고 있습니다.
중동 및 아프리카 유방암 치료제 시장 개요
중동 및 아프리카의 유방암 치료제 시장은 UAE, 사우디아라비아, 남아프리카 및 기타 중동 지역으로 구분됩니다. & 아프리카. 변화하는 의료 인프라와 정부와 국제 기업 간의 민관 파트너십이 국가의 의료 부문을 강화하고 있습니다. 이러한 파트너십과 민영화 노력은 국가 경제를 변화시키려는 사우디 정부의 \"비전 2030\" 전략에 포함된 정책과 일치합니다. 국제 무역청(International Trade Administration)에 따르면 사우디아라비아 정부는 비전 2030의 일환으로 국가 의료 인프라 구축에 약 650억 달러를 투자했습니다. 또한, 2030년까지 민간 부문 기여도를 40%에서 65%로 늘릴 계획입니다. 병원 290개와 1차 의료센터 2,300개를 민영화하는 데 주력한다. 인프라 및 혁신에 대한 투자 증가는 시장 성장을 촉진할 것으로 예상됩니다.
2023년 6월, MSD GCC는 아부다비 보건부(DoH)와 종양학 연구 파트너십을 확대했습니다. BIO International Convention 2023에서 체결된 이번 거래는 두 회사 간의 장기적인 협력이 지속됨을 의미합니다. 새로운 파트너십의 틀 내에서 양 당사자는 비소세포폐암과 삼중음성유방암에 초점을 맞춘 종양학 분야의 두 가지 관찰 연구를 시작하기 위해 협력할 것입니다. 이 연구의 목표는 이러한 질병과 관련된 의료 문제를 해결하고 환자 결과를 개선하는 능력을 향상시키는 것입니다. 따라서 국내에서 새롭고 혁신적인 제품에 대한 인식과 개발을 확산시키려는 기업의 노력이 증가하는 것은 UAE 유방암 치료제 시장의 성장에 크게 기여합니다.
2021년 10월, 쿠웨이트 국립은행(NBK)은 유방암 인식의 달을 맞아 여성 건강을 홍보하기 위한 연례 캠페인을 시작했습니다. 이 캠페인은 유방암에 대한 사회적 인식을 높이고 예방 방법을 홍보하기 위한 Banks의 지속적인 캠페인의 일부입니다. 따라서 위에서 언급한 요인은 유방암 치료제 시장 성장을 크게 촉진합니다.
중동 및 아프리카 유방암 치료제 시장 수익 및 2030년 예측(미화 백만 달러)
중동 및 아프리카 유방암 치료제 시장 세분화
중동 및 아프리카 유방암 치료제 시장은 약물 치료, 유방암 유형 및 유통 채널을 기준으로 분류됩니다.
중동 및 아프리카 유방암 치료제 시장은 약물치료를 기준으로 표적 약물치료, 호르몬 약물치료, 화학요법, 면역치료/생물학적 치료 등으로 분류됩니다. 표적 약물 치료 부문은 2022년에 더 큰 점유율을 차지했습니다. 표적 약물 치료 부문은 2022년에 더 큰 점유율을 차지했습니다. 표적 약물 치료 부문은 abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab 및 기타 표적 약물 치료로 더 세분화됩니다. 또한 호르몬 약물 치료 부문은 선택적 에스트로겐 수용체 조절제, 아로마타제 억제제 및 선택적 에스트로겐 수용체 하향 조절제로 분류됩니다.
유방암 유형별로는 중동 및 아프리카 유방암 치료제 시장이 호르몬 수용체인 HER2+ 유방암과 삼중음성 유방암으로 구분된다. 2022년에는 호르몬 수용체 부문이 더 큰 점유율을 차지했습니다.
유통 채널별로 중동 및 아프리카 유방암 치료제 시장은 병원 약국, 약국, 소매 약국, 온라인 약국으로 분류됩니다. 2022년에는 병원 약국 부문이 더 큰 점유율을 차지했습니다.
국가별로 중동 및 아프리카 유방암 치료제 시장은 남아프리카, 사우디아라비아, UAE, 기타 중동 및 아프리카 지역으로 분류됩니다. 사우디아라비아는 2022년 중동 및 아프리카 유방암 치료제 시장을 장악했습니다.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd와 Amgen Inc는 중동 및 아프리카 유방암 치료제 시장에서 활동하는 선도적인 회사 중 일부입니다.
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Breast Cancer Therapeutics Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market - Middle East & Africa Market Analysis
5.1 Middle East & Africa Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy
6.1 Overview
6.2 Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 Middle East & Africa Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 Middle East & Africa Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type
7.1 Overview
7.2 Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Breast Cancer Therapeutics Market -Country Analysis
9.1 Middle East & Africa Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
9.1.1 Overview
9.1.2 Middle East & Africa Breast Cancer Therapeutics Market, Breakdown, by Country- Revenue (2022) (US$ Million)
9.1.3 Middle East & Africa Breast Cancer Therapeutics Market, by Countries, 2022 and 2030 (%)
9.1.3.1 Saudi Arabia
9.1.3.1.1 Saudi Arabia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 Saudi Arabia: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 Saudi Arabia: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 Saudi Arabia: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 Saudi Arabia: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 Saudi Arabia: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 UAE
9.1.3.2.1 UAE Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 UAE: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 UAE: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 UAE: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 UAE: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 UAE: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 South Africa
9.1.3.3.1 South Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 South Africa: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 South Africa: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 South Africa: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 South Africa: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 South Africa: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.4 Rest of Middle East & Africa
9.1.3.4.1 Rest of Middle East & Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.4.2 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.1 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.2.2 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.4.3 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.4.4 Rest of Middle East & Africa: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. Middle East & Africa Breast Cancer Therapeutics Market Segmentation
Table 2. Middle East & Africa Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. Middle East & Africa Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. Saudi Arabia Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. Saudi Arabia Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. Saudi Arabia Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. Saudi Arabia Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. Saudi Arabia Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. UAE Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. UAE Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. UAE Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. UAE Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. UAE Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. South Africa Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. South Africa Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. South Africa Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. South Africa Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. South Africa Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Rest of Middle East & Africa Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 20. Rest of Middle East & Africa Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 21. Rest of Middle East & Africa Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 22. Rest of Middle East & Africa Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Middle East & Africa Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 24. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 25. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 26. Glossary of Terms, Breast Cancer Therapeutics Market
List of Figures
Figure 1. Middle East & Africa Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. Middle East & Africa Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Middle East & Africa Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: Middle East & Africa Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Middle East & Africa Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. Middle East & Africa Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. Saudi Arabia Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. UAE Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. South Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Rest of Middle East & Africa Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Growth Strategies in Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Teva Pharmaceutical Industries Ltd
9. Amgen Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa breast cancer therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in Middle East & Africa breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution